ijtos 2024; doi 10.22376/ijtos.2023.2.1.1-9

International Journal of Trends on OncoScience

ISSN-2583-8431

Precision Targeting and Genetically Modified T Cells for Targeting Cancer Cells

[1*,] Dr Ammar A. Razzak Mahmood [2], Sudhakar Srinivasan, [3], Challaraj Emmanuel E. S

[1*,] *Dept. of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad. Bab Al-Mouadam,10001. Baghdad Iraq.*

[2,] *Tutor, Department of Biochemistry, Annapoorna Medical College and Hospital, Salem, India.*

[3,] *Department of Life Sciences, Kristu Jayanti College (Autonomous), K Narayanapura, Kothanur Post, Bengaluru-560077, Karnataka, India*

Abstract: In this review cancer treatment, despite notable progress, challenges persist globally. Traditional methods like surgery, chemotherapy, and radiotherapy, while effective, often compromise patients' overall quality of life due to side effects. Immunotherapeutic strategies, especially Chimeric Antigen Receptor T cells, show promise by leveraging the immune system to target tumors independently of certain immune escape mechanisms. However, CAR-T cells' specificity to surface antigens limits their applicability. Precise cancer management demands ongoing research to refine and broaden these therapies. Employing CAR or T-cell receptor therapies, genetic engineering enhances T-cell antigenic specificity, optimizing cancer immunotherapy precision. CARs, synthetic receptors engineered for tumor antigen recognition, represent a groundbreaking approach, intertwining immunotherapy, gene therapy, and cancer therapy. The human immune system's ability to discern self from non-self-entities forms the basis of immunotherapy, fostering innovative modalities that selectively target cancer cells. CAR-T therapy, with FDA approval for leukemia and lymphoma, holds transformative potential but faces safety and efficacy challenges. Advances, including mitigating cytotoxicity and enhancing therapeutic efficacy, show promise. Utilizing genetic alteration, CARs have shown efficacy in the treatment of hematologic malignancies, particularly CD19 CARs in B cell blood cancers. Current study is investigating the potential uses of CAR-T cell treatment in patients with lymphoma and myeloma.

Keywords: Precision Targeting, Genetically Modified T Cells, Targeting, Precision Medicine, Immunotherapy, Cancer Cells.

***Corresponding Author**

Dr Ammar A. Razzak Mahmood , Dept. of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad. Bab Al-Mouadam,10001. Baghdad Iraq.

Received On 28 November 2023

Revised On 7 December 2023

Accepted On 13 December 2023

Published On 5 January 2024

Funding This research did not receive any specific grant from any funding agencies in the public, commercial or not for profit sectors.

Citation Dr. Ammar A. Razzak Mahmood,Sudhakar Srinivasan,Challaraj Emmanuel E.S , Precision Targeting and Genetically Modified T Cells For Targeting Cancer Cells.(2024).Int. J. Trends in OncoSci.2(1), 1-9 http://dx.doi.org/10.22376/ijtos.2023.2.1.1-9

1. INTRODUCTION

Despite significant advancements in cancer treatments in recent years, cancer continues to pose formidable challenges globally. Conventional therapeutic modalities, encompassing surgical interventions, chemotherapy, and radiotherapy, have demonstrated efficacy in achieving short-term curative outcomes; however, their utility is accompanied by deleterious side effects that invariably compromise the overall quality of life for cancer patients [1]. Notably, contemporary immunotherapeutic strategies have emerged as promising alternatives, leveraging the inherent capabilities of immune cells to combat malignancies. One such paradigm involves the use of Chimeric Antigen Receptor T cells, which possess the distinctive ability to recognize and eliminate tumor cells independently of major histocompatibility complex molecules. This renders them impervious to immune escape mechanisms employed by tumor cells through downregulation of MHC molecule expression [2]. It is imperative to underscore, however, that CAR-T cells exhibit selectivity limited to tumor antigens expressly presented on cell membranes, thereby conferring a high degree of specificity to their target recognition [3]. This inherent specificity, while advantageous in ensuring targeted therapeutic interventions, also imposes constraints on the breadth of applicability. Hence, the intricate interplay between the molecular characteristics of tumor cells and antigenic landscape dictates the efficacy and precision of CAR-T cell-based immunotherapy. This nuanced understanding underscores the necessity for continued research endeavors aimed at refining and expanding the scope of these innovative therapeutic modalities in the relentless pursuit of effective and tailored cancer management strategies. The efficacy of cancer immunotherapeutic modalities hinges upon the antigenic selectivity inherent in T-cell responses. This selectivity stands amenable to augmentation through the molecular manipulation and reprogramming of T-cells, thereby affording a heightened affinity for antigens exhibiting pronounced overexpression within neoplastic tissues. The personalized approach entails the genetic engineering of endogenous T-cells to impart expression of engineered T-cell receptors (commonly referred to as TCR therapies) or Chimeric Antigen Receptors (CARs). This orchestrated molecular intervention serves to potentiate and refine the antigenic specificity of T-cell populations, thereby elevating the precision and efficacy of cancer immunotherapeutic strategies [4]. Chimeric antigen receptors (CARs) represent a distinctive class of receptors meticulously engineered to selectively recognize and engage specific tumor antigens, thereby orchestrating a functional reprogramming of T lymphocytes. Through the genetic modification of T lymphocytes to express these synthetic receptors with a dedicated focus on cancer cell targeting, the therapeutic paradigm encapsulates multifaceted designations such as immunotherapy, gene therapy, or cancer therapy [5]. The innate human defense system proficiently discriminates between self and non- self entities, encompassing bacteria, viruses, and aberrant cancer cells within its purview. The discernment of tumor cells is contingent upon their acquired antigenicity and immunogenicity, emanating from the manifestation of foreign antigens [6]. Immunotherapy, also known as biotherapy, refers to a theoretical framework where the body's immune system has the ability to recognize and fight against disease-causing microorganisms and cancerous cells. The increased understanding of the immune system has led to a rise in the creation of new and advanced methods of immunotherapy. These methods use strategic techniques to activate the immune system in a selective way, primarily focusing on attacking cancerous cells. The use of Chimeric Antigen Receptor T-cell (CAR-T) therapy in cancer treatment has seen significant progress, becoming a crucial approach for managing blood-related cancers. [7]. The United States Food and Drug Administration (FDA) granted regulatory approval to Kymriah in August 2017 and Yescarta in October 2017. This approval was a significant occasion, as it endorsed the use of CAR-T cell medicines for treating leukemia and lymphoma. Positioned as an innovative therapeutic approach, CAR-T cell therapy has the potential to significantly improve clinical outcomes for many patients. However, its success as a leading treatment option depends on overcoming existing challenges related to safety and effectiveness [8]. Fortunately, a range of approaches designed to reduce the harmful effects on cells while simultaneously enhancing the effectiveness of CAR-T cells has been developed and shown significant progress. This has resulted in meaningful advancements in controlling the activity of CAR-T cells [9]. The use of T lymphocytes targeting specific antigens has shown significant potential in the fields of HIV and cancer treatment. Alongside the execution of immune checkpoint blockade techniques [10]. This approach is causing a significant and fundamental change in the field of cancer immunotherapy. One particularly notable technique involves using T cells from peripheral blood that are genetically modified to express chimeric antigen receptor (CAR) genes. CARs consist of a complex molecular structure that includes an extracellular single-chain variable fragment (scFv) as the targeting component, a transmembrane spacer, and intracellular signaling/activation domains. The administration of genetically modified T cells with chimeric antigen receptors (CARs) has shown exceptional effectiveness in the management of blood cancers, namely in acute and chronic B cell leukemias. Among these CARs, those targeting CD19 have shown remarkable performance. [11]. Furthermore, current research is closely examining the possible uses of CAR T cell treatment in patients suffering from lymphoma and myeloma.

1.1 Framework of Chimeric Antigen Receptor T Cell Therapy

Chimeric Antigen Receptor immunotherapy is gaining increasing recognition as a potentially efficacious treatment for several types of malignancies. CAR immunotherapy is an innovative approach in gene therapy research that aims to alter T lymphocytes to selectively eliminate cancer cells. The first stage of this therapy involves leukapheresis, a meticulous operation aimed at extracting the patient's peripheral blood. This intricate process has been extensively examined in prior studies [12]. Apheresis, a commonly used technique for blood separation, is crucial in the early phases of CAR immunotherapy. After being separated, the blood components undergo genetic modification before being reintroduced into the patient's circulatory system. This systematic process of organizing and strategizing the sequence of actions effectively encompasses the intricate range of CAR [13]. T cells are extensively amplified in the laboratory and then reintroduced into the patient. This procedure involves the manipulation of genetic material [14]. Through the use of this treatment method, the patient is provided with an immune milieu that is prepared for fast and efficient anti-tumor response. The chimeric antigen receptor (CAR) is a crucial element of the genetically modified T cell.

The T cell's CAR molecule contains essential proteins for precise recognition of malignant cells and for inducing heightened activation to eradicate these pathological entities. Upon administration, the CAR T cells undergo proliferation and long-term persistence within the patient's physiological milieu, therefore offering sustained control over tumor occurrences and a possible safeguard against relapses [15]. Prior to commencing this therapy, the individual's T cells need to be obtained via an outpatient leukapheresis procedure [16]. After being acquired, these T cells are sent to a specialized facility for meticulous modification and manufacturing procedures. After genetic modification, the CAR-equipped T cells are reintroduced into the patient, concluding a process that typically lasts around two weeks. Throughout the cell-development phase, the patient often undergoes targeted chemotherapeutic treatments that are meticulously designed to prime the immune system and provide optimal assistance for the subsequent inoculation of CAR T cells. [17].

1.2 Designing CAR T Cells for Effective Cancer Treatment

The CAR, or chimeric antigen receptor, serves as the crucial element for cellular identification and stimulation in CAR-T cell immunotherapy. This innovative approach effectively separates the TCR's specificity from the binding of antigens, enabling CAR-T cells to independently identify and interact with tumor-specific antigens. Importantly, CAR-T cells merge the ability to recognize antigens with the cytotoxic capacity of traditional T cells, establishing them as a potent tool in the fight against cancer [18]. CD19 is the primary target for therapy when dealing with hematological neoplasms [19]. CD19 is highly expressed on the surface of B cells, making it a prime target for the development of CAR-T cells. The research focused on the creation and widespread application of CD19 CAR-T cells, which are a kind of adoptive immunotherapy. This project was carefully planned and successfully carried out, demonstrating that this therapy is a viable and effective treatment option for hematological tumors [20]. The distinctiveness of chimeric receptors is evidenced by their capacity to integrate or separate distinct essential functions, such as activation, stimulation, and recognition, across various chains within a receptor molecule, replicating the complexities inherent in the original T cell receptor structure. The technique entails constructing a custom chimeric receptor for T cells by incorporating single-chain variable fragment components into the hinge region that separates the scFv from the cell membrane. When scFv fragments are displayed on cell surfaces alongside other small functional entities, they enhance the activation of the cytolytic activity intrinsic to the genetically modified T cell. Collectively, these coordinated interactions create a "biological therapeutic" within the immune system to collaboratively combat cancer [21]. Ensuring the successful implementation of CAR T-cell therapy requires maintaining safe, reliable, and efficient gene transfer platforms. Leukapheresis is the method used to gather self T-cells, which are then isolated and genetically altered outside the body using both viral and non-viral transfection methods. Subsequently, the genetically engineered T-cells are cultivated in significant quantities. Before infusing the CAR T-cell product, patients typically undergo lymphodepleting chemotherapy following thorough quality control assessments [22]. The discovery of chimeric receptors occurred in 1989 via research undertaken by Eshhar's team at the Weizmann Institute of Science in Israel. The extracellular domain of the CAR consists of the moiety for binding antigens and a spacer region. The components for binding antigens may be either endogenous ligands binding to their specific receptors, human Fab fragments chosen from phage display libraries, or single-chain fragment variables derived from antibodies [23]. Mouse monoclonal antibodies, humanized antibodies , or completely human antibodies serve as the origin for the scFv, which is a variable fragment of a monoclonal antibody. Its primary role is to recognize and bind to specific tumor-specific antigens present on the surfaces of tumor cells.



Fig 1: Designing CAR T Cells for Effective Cancer Treatment

1.3 Benefits of CAR Therapy Compared to Other Treatment Modalities

Patients undergoing chimeric antigen receptor T-cell therapy commonly experience transient blood-related irregularities as a result of the treatment. This is identified by a temporary decline in blood cell counts, leading to a clinical condition marked by fatigue, heightened susceptibility to infections, and the need for transfusion assistance. Additionally, some individuals may undergo collateral B-cell depletion, resulting in a condition referred to as B-cell aplasia. Significantly, B cells play a crucial role in antibody production, and individuals with B-cell aplasia require frequent intravenous injections of antibodies to mitigate their increased vulnerability to infections [24]. Furthermore, following CAR T-cell treatment, several adverse effects may manifest, such as cytokine release syndrome and neurological complications, all of which can have significant therapeutic implications. CRS is manifested by a variety of signs, including an elevated body temperature, skin rash, headache, and abnormalities in blood pressure. Concurrently, neurologic toxic effects encompass a broad spectrum of symptoms, ranging from mild manifestations such as headaches to more severe ones like delirium, seizures, and disorientation. These symptoms may manifest either rapidly, within minutes or hours, or gradually over days or even weeks following treatment. Although most adverse effects are typically temporary, it is essential to underscore the few instances in which long-term issues have been documented [25]. The primary advantage of Chimeric Antigen Receptor T cell therapy compared to other cancer treatment methods is its ability to promptly intervene and require only a single transfer of CAR T cells. Therefore, a careful duration of two to three weeks, marked by meticulous attention to specifics and vigilant monitoring, is adequate for the patient's comprehensive therapy. The text is enclosed in the tags [26]. CAR T cell therapy, regarded as a contemporary therapeutic approach, demonstrates enduring efficacy that may persist for many decades due to the prolonged presence of these cells inside the recipient's body. By residing in the body for an extended period, CAR T cells acquire the ability to identify and eliminate cancer cells upon their reappearance. Thus, a cautious timeframe of two to three weeks, characterized by meticulous attention to specifics and vigilant supervision, is satisfactory for the patient's comprehensive therapy. CAR T cell therapy, viewed as a contemporary therapeutic approach, exerts a lasting impact that may endure for many decades due to the extended presence of these cells inside the recipient's body. The prolonged residence of CAR T cells enables them to effectively identify and eliminate cancer cells upon recurrence [27]. Clinical investigations targeting blood-related cancers have demonstrated the remarkable success of CAR T cell therapy in completely eradicating cancer, even in cases where relapse occurs due to refractory conditions following multiple transplantations. Importantly, T cells that have been modified with mesothelin-specific CAR mRNA have been successfully implemented and shown the ability to induce robust antitumor reactions in the presence of solid tumors [28]. Moreover, the creation of two distinct chimeric antigen receptors (CARs) that exclusively target the human leukocyte antigen A2 has enabled the practical use of CAR technology in the field of organ donation. Within this set of Chimeric Antigen Receptors, one has an internal signaling domain known as dCAR, while the other incorporates a CD28 CD3d signaling domain, referred to as CAR. The preliminary study of CAR T cell therapy targeting the tumor antigen 5T4 in ovarian cancer has demonstrated favorable outcomes [29].

1.4 Utilizing CAR-T cell-based therapy for the treatment of solid tumors

A prominent treatment approach for blood cancers has been the use of Chimeric Antigen Receptor T cells. However, there are numerous inherent challenges in applying this advancement for treating solid tumors. The number 30 is denoted as 30. Three primary obstacles arise from the complexities of solid tumor biology when applying CAR-T cell therapy for these specific malignancies. A significant challenge is the absence of well-defined and widely applicable objectives, along with the diverse features of solid tumors. Additionally, the optimal attainment of therapeutic benefits is impeded by inadequate penetration of CAR-T cells into the microenvironment of solid tumors. Furthermore, the intricate interplay within the tumor microenvironment is a crucial factor in determining the overall efficacy of CAR-T cell treatment. Solid tumor tissues are more intricate than hematological tissues, as they consist of several tumor cells that exhibit distinct protein expression patterns. The need to be inclusive across the entire range of cellular heterogeneity poses a significant challenge in selecting suitable targets [31]. Solid tumor cells originate from normal tissues, posing a challenge in distinguishing antigens present only in cancerous cells. The issue lies in the potential for nonspecific targeting of normal cells, resulting in on-target, off-tumor side effects [32]. Two techniques to address these safety concerns include reducing receptor affinity and exploring multi-targeted CAR-T cells to minimize undesirable interactions with healthy tissues. The heterogeneity of solid tumors significantly influences the therapeutic approach for these tumor types. The efficacy of CAR-T cell treatment depends on its ability to overcome the robust barriers established by vascular endothelial cells and effectively traverse the dense tumor tissue. The tumor microenvironment complicates the therapy process by inhibiting the release of vascular-related factors, adding an additional layer of challenge [33]. Therefore, the use of CAR-T cell therapy for solid tumors is constrained by its intrinsic need to traverse the vascular endothelial barrier and navigate the challenging terrain of the tumor microenvironment to achieve optimal target interaction and therapeutic impact. Solid tumors present distinct challenges not seen in hematologic malignancies. Identifying specific tumor antigens that demonstrate extensive and intense expression has proven to be a challenging endeavor. The presence of a tumor has been observed [34]. Following the challenging journey, CAR T cells must successfully navigate through the structural elements seen in solid tumors to trigger targeted destruction of the precise Target Antigen, surpassing concerns about variations in antigenic properties or loss. However, T cell function rapidly declines for various reasons, even with effective movement and infiltration [35]. Firstly, the tumor microenvironment is characterized by a hostile setting, consisting of hypoxia, acidic pH, oxidative stress, and dietary limitation. Furthermore, the decrease in T cell efficacy is attributed to inhibitory soluble factors and cytokines. Additionally, immune cell populations that inhibit the tumor microenvironment include regulatory T cells, myeloid-derived suppressor cells, and either neutrophils or macrophages. Ultimately, T cells have inherent mechanisms controlling their activity, evident in the heightened presence of inhibitory receptors on their surface and inside their cytoplasm. The comprehensive nature of these intricate

problems underscores the complex setting in which solid tumors require the passage of CAR T cells, necessitating deliberate interventions to enhance treatment outcomes [36].



Fig 2 : Immunosuppressive tumor micro environment.

1.5 Investigating the use of CART T Cell Therapy in the treatment of cancer

The efficacy of chimeric antigens receptors T-cell therapy is being shown via thorough evaluations conducted in scientific settings and in animal models, using either orthotopic or metastatic xenografts. Recent research indicates that CAR T-cells that produce receptors for chemokine, namely those that promote CXCR2, has a greater capacity to go towards interleukin-8 (IL-8) 37. In xenograft animal models, CAR T-cells expressing CXCR2 exhibited strong anticancer properties against avb6-expressing pancreatic tumors. These studies corroborate the hypothesis. CD133-CAR T-cells have demonstrated significant efficacy in research for reducing the metastasis capacity of colorectal, liver, and pancreas tumors. Human anti-HER2 CAR T-cells have shown favorable targeting characteristics by triggering apoptosis in HER2-overexpressing breast cancer cells. Furthermore, one intriguing field of study in tumor chemotherapy focuses on the discovery of mesothelin as a biomarker by the utilization of targeted CAR T-cells 38. A new therapy using CAR T-cells that specifically target intercellular adhesion molecule 1 (ICAM-1) has been developed and shown to be highly successful in preliminary studies. This study is the first investigation of CAR T-cell therapy for advanced thyroid cancer. The number is 39. However, there are barriers that hinder the practical use of anti-ICAM 1-CAR T-cells in therapy. These considerations include, but are not limited to, the possibility of self-reactivity that reduces the development and survival in vitro in patients with thyroid cancer. Various completed and continuing clinical studies have used CAR T-cells for the treatment of glioblastoma. The effectiveness of intravenous EGFRvIII CAR T-cell therapy was thoroughly assessed in the first human clinical trial, including 10 patients with recurrent GBM. 40. The novel idea of a universal CAR T cell, with a tri-cistronic transgene encoding CAR molecules that specifically target HER2, IL-13Ra2, and EphA2, has effectively resolved concerns about patient-specific variations and has shown 100% efficacy in targeting all GBM tumor cells. The effectiveness of anti-CD19 chimeric antigens receptors T-cell therapy has been clearly shown in cohorts of patients with relapsed or refractory (R/R) B-cell malignancies, including both pediatric and adult populations. The treatment strategy has displayed exceptional efficacy in managing acute lymphoblastic leukemia, also called chronicle lymphocytic leukemia, and B-cell non-Hodgkin lymphoma. Significantly, treatment trials have shown complete remission rates that vary between 70% and 94%. The number is 41. Although CD19-targeting CAR T-cells have shown an excellent track record in treatment lymphocyte leukemias and a notable percentage (10% to 20%) of juvenile B-cell Acute Lymphoblastic Leukemia patients who have received CD19-directed chemotherapy have had antigen escape. Antigen escape refers to the phenomenon when malignant cells exhibit a decrease or complete lack of detectable CD19 expression on their surface 42. Acute lymphoblastic leukemia has shown a very advantageous response to CAR-T cytotherapy, making it particularly advantageous for leukemias that have had fatal relapse or have not responded to treatment. CD19 is an ideal target for B-ALL treatment since it is expressed more on tumor cells than other molecular markers of B cells. The number is 43. Moreover, the use of CAR-T cells in lymphoma therapy requires the presence of CD19, CD20, or CD30. Most B-cell lymphomas express CD20, and CAR-T cells expressing CD20 have shown great success in numerous NHL therapies.

1.6 Adverse effects of CART T cell treatment

Cytokine release syndrome is the primary negative consequence linked to CAR-T cell treatment [44]. Cytokines releasing disorder is an inflammatory response to treatment that typically manifests a few days after the first infusion. The occurrence is initiated by a substantial rise in cytokines and the fast stimulation and proliferation of CAR-T cells inside the organism [45]. CRS, a clinical condition, is distinguished by the presence of minor symptoms like fever, fatigue, headache, skin rash, joint pain, and muscle pain. The user's input is represented by the number [46]. The manifestation of neurological complications stemming from CAR-T cell

treatment for leukemia is an unexpected and indeterminate phenomenon. The experiment using CD19-specific CAR-T cells often observed neurologic impairment, although the underlying reason of this harm remained little comprehended. It is widely recognized that CAR T-cell therapies can lead to notable adverse effects in various forms of cancer, such as immune effector cell associated neurotoxicity syndrome (ICANS), tumor lysis syndrome (TLS), graft-versus-host disease (GVHD), and cytokine release syndrome (CRS). Heightened concentrations of cytokines in the bloodstream result in a fast rise in T-cell stimulation, which in turn triggers CRS [47]. Neurological toxicities, particularly in those receiving antiCD19 CAR T-cell treatment for lymphoma, may result in B-cell aplasia, confusion, lack of response, and seizures [48] [49]. Graft-versus-host disease (GVHD) often occurs in patients who receive allogeneic lymphocytes from human leukocyte antigen (HLA)-matched unrelated donors, because to the immunological reaction induced by non-cancerous cells. Tumor lysis syndrome (TLS) has emerged as a common undesirable outcome associated with the administration of chimeric antigen receptor T-cell (CAR-T) treatment for hematological malignancies. The user's input is "[50]." The therapeutic intervention against cancer cells leads to a significant release of intracellular components that exceeds the metabolic capacity of the kidneys and liver. As a consequence, metabolic waste products build up, causing numerous disturbances to the body's physiological balance. Brain cytokine release syndrome (CRS) is a neurotoxic disorder that occurs when there is an increased presence of cytokines in the brain. The condition is distinguished by symptoms such as fainting, confusion, difficulty speaking, and convulsions. The planned use of corticosteroids in therapeutic situations has been shown to be beneficial in mitigating neurotoxicity. This is because they have the capacity to cross the blood-brain barrier, a characteristic that is noticeably lacking in several monoclonal antibodies. Therefore, when tumor-specific antigens are expressed in cells other than malignant cells, it results in the formation of on-target off-tumor toxicity (OTOTT) [36]. Although CAR-T cells have high efficacy in targeting tumors, they may also cause unintentional harm by attacking both cancerous and healthy cells [51]. While CAR T cell therapy is an innovative method for treating cancer, it is not devoid of difficulties, as seen by a comprehensive list of negative side effects that often occur. The present research indicates that there are many harmful effects, such as allergies, B cell aplasia, cytokine release syndrome (CRS), neurological toxicity, and tumor lysis syndrome [52]. The key issue is on the proliferation of CAR T cells, which delicately controls the production of cytokines within the body's natural environment. The excessive release of cytokines, which is intended to eradicate cancer cells, results in a range of clinical symptoms associated with the toxicity of cytokine release syndrome (CRS). The range of symptoms linked to this illness is wide, including milder signs such as chills, fever, headache, nausea, and fatigue, as well as more serious indications like rapid heart rate, low blood pressure, and changes in the capacity of capillaries to allow substances to pass through [53]. A noteworthy occurrence to emphasize is B cell aplasia, which happens when CAR T cells attack both benign and malignant cells without discrimination, primarily targeting antigens present on the surface of T or B cells [54]. As a consequence, the clinical appearance that occurs due to this unintentional injury is characterized by the absence of functioning B cells. The complex interplay of these many components highlights the need of carefully analyzing and cautiously managing the complicated web of adverse effects associated with CAR T cell therapy [55]. It is essential for CARs to have an appropriate affinity for binding to antigens in order to accurately detect antigens found on cancer cells, initiate signaling pathways of chimeric antigen receptors (CARs), and activate T-cells. To ensure an optimal balance, it is necessary to maintain a level of attraction that is strong enough to aid in the identification of tumor cell antigens, while avoiding an excessively strong attraction that would cause activation-induced death in CAR-expressing T cells and result in harmful toxicities. This concept is discussed in detail in the comprehensive review. While affinity is undoubtedly the main factor, the effect on CAR-T cell activity may differ among single-chain variable fragments (scFvs) that have the same affinities, hence increasing the complexity of the situation [56]. The hinge or spacer area pertains to the extracellular structural domain that extends the binding moieties from the transmembrane domain. This section plays a crucial function by facilitating the required flexibility to overcome steric hindrance, adding to the overall length of the structure, and providing easy access for the antigen-binding domain to the targeted epitope. Optimal selection of spacer length sometimes requires a trial-and-error approach, taking into account the distinct attributes of each individual combination of antigen-binding domains. Attaining best performance requires rigorous customization [57]. The main obstacles in the domain of CAR T-cell therapy are enhancing the enduring efficacy of CAR T-cells in live beings and devising strategies to mitigate the adverse impacts of the treatment. To avoid relapse, it is necessary for CAR T-cells to endure and sustain their effectiveness for an extended period of time. Patients who had infusion treatment have shown the continued presence of anti-CD19 CAR T-cells for an extended period of time, spanning many years [58]. The persistent existence of T-cells might be associated with the immune responses triggered by the transgene, the durability of transgenic expression, and the conditions in which T-cell proliferation takes place ex vivo [59].

2. CONCLUSION

The emergence of Chimeric Antigen Receptor therapy signifies a potentially groundbreaking change in the approach to treating neoplastic diseases that are resistant or have recurred. CAR T-cell therapy is a personalized pharmacological intervention for cancer treatment that differs greatly from standard procedures. It is designed with distinct features unique to each patient and has the ability to self-replicate. Although CAR treatment has achieved significant triumphs, particularly in the realm of hematological cancers, these accomplishments just mark the first phase of a comprehensive exploration into the vast potential of CAR-directed immune regulation. This inquiry expands its range to include the challenging task of eradicating non-hematological malignancies that exhibit resistance, metastasis, or recurrence. Immunotherapy, recognized for its therapeutic efficacy, is a crucial method for treating cancer. Lately, there has been a fervent exploration of several immunotherapeutic approaches, such as gene therapies, antibody treatments, and adoptive cell therapies, resulting in groundbreaking findings. Tecartus (brexucabtagene autoleucel), a genetically modified treatment that uses chimeric antigen receptor T cells has shown significant efficacy, particularly in hematological cancers like mantle cell lymphoma (MCL). Despite these developments, effectively managing cytotoxicity after CAR-T cell infusion remains a challenging hurdle, underscoring the

ongoing difficulty in enhancing these therapies. It is important to acknowledge that the area of CAR-T cell treatments is still in its early stages, and a comprehensive understanding of the scientific intricacies associated with them is crucial before contemplating their widespread use.

3. AUTHORS CONTRIBUTION STATEMENT

Dr Ammar A. Razzak Mahmood, Sudhakar Srinivasan, and Challaraj Emmanuel E. S contributed substantially to conception and design, or acquisition of data, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; and final approval of the version to be published.

4. CONFLICT OF INTEREST

Conflict of interest declared none.

5. REFERENCES

1. Zhang JP, Zhang R, Tsao ST, Liu YC, Chen X, Lu DP et al. Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient. Blood Adv. 2018 Jul 24;2(14):1691-5. doi: 10.1182/bloodadvances.2018017004, PMID 30026294.
2. Akatsuka Y. TCR-like CAR-T cells targeting MHC-bound minor histocompatibility antigens. Front Immunol. 2020 Feb 28;11:257. doi: 10.3389/fimmu.2020.00257, PMID 32184779.
3. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018 Oct 1;8(10):1219-26. doi: 10.1158/2159-8290.CD-18-0442, PMID 30135176.
4. June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018 Mar 23;359(6382):1361-5. doi: 10.1126/science.aar6711, PMID 29567707.
5. Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020 Oct 12;38(4):473-88. doi: 10.1016/j.ccell.2020.07.005, PMID 32735779.
6. Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019 Mar 14;20(6):1283. doi: 10.3390/ijms20061283, PMID 30875739.
7. Feng J, Xu H, Cinquina A, Wu Z, Chen Q, Zhang P et al. Treatment of aggressive T cell lymphoblastic lymphoma/leukemia using anti-CD5 CAR T cells. Stem Cell Rev Rep. 2021 Apr;17(2):652-61. doi: 10.1007/s12015-020-10092-9, PMID 33410096.
8. Benjamini O, Shimoni A, Besser M, Shem-Tov N, Danylesko I, Yerushalmi R et al. Safety and efficacy of CD19-CAR T cells in Richter's transformation after targeted therapy for chronic lymphocytic leukemia. Blood. 2020 Nov 5;136;Suppl 1:40. doi: 10.1182/blood-2020-138904.
9. Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D et al. FCγ chimeric receptor-engineered T cells: methodology, advantages, limitations, and clinical relevance. Front Immunol. 2017 Apr 27;8:457. doi: 10.3389/fimmu.2017.00457, PMID 28496440.
10. Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092, PMID 27454297.
11. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E. CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. The Journal of clinical investigation. 2016 Jun 1;126(6):2123-38.
12. Korell F, Laier S, Sauer S, Veelken K, Hennemann H, Schubert ML et al. Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL. Cells. 2020 May 15;9(5):1225. doi: 10.3390/cells9051225, PMID 32429189.
13. Liu H, Xu Y, Xiang J, Long L, Green S, Yang Z et al. Targeting alpha-fetoprotein (AFP)–MHC complex with CAR T-cell therapy for liver cancer. Clin Cancer Res. 2017 Jan 15;23(2):478-88. doi: 10.1158/1078-0432.CCR-16-1203, PMID 27535982.
14. Eisenberg V, Hoogi S, Shamul A, Barliya T, Cohen CJ. T-cells "à la CAR-T (e)"–Genetically engineering T-cell response against cancer. Adv Drug Deliv Rev. 2019 Feb 15;141:23-40. doi: 10.1016/j.addr.2019.01.007, PMID 30653988.
15. Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018 Jun 1;23(6):1175-82. doi: 10.1016/j.drudis.2018.02.012, PMID 29501911.
16. Hutt D, Bielorai B, Baturov B, Z'orbinski I, Ilin N, Adam E et al. Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients. Transfus Apher Sci. 2020 Aug 1;59(4):102769. doi: 10.1016/j.transci.2020.102769, PMID 32414613.
17. Truong NTH, Gargett T, Brown MP, Ebert LM. Effects of chemotherapy agents on circulating leukocyte populations: potential implications for the success of CAR-T cell therapies. Cancers. 2021 May 6;13(9):2225. doi: 10.3390/cancers13092225, PMID 34066414.
18. Mi JQ, Xu J, Zhou J, Zhao W, Chen Z, Melenhorst JJ et al. CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Front Med. 2021 Dec 18;15(6):783-804. doi: 10.1007/s11684-021-0904-z, PMID 34921673.
19. Liu B, Yan L, Zhou M. Target selection of CAR T cell therapy in accordance with the TME for solid tumors. Am J Cancer Res. 2019;9(2):228-41. PMID 30906625.
20. Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current progress in CAR-T cell therapy for hematological malignancies. J Cancer. 2021;12(2):326-34. doi: 10.7150/jca.48976, PMID 33391429.
21. Watanabe K, Nishikawa H. Engineering strategies for broad application of TCR-T-and CAR-T-cell therapies. Int Immunol. 2021 Nov 1;33(11):551-62. doi: 10.1093/intimm/dxab052, PMID 34374779.
22. Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer

treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 2016 Jan 6;56:59-83. doi: 10.1146/annurev-pharmtox-010814-124844, PMID 26738472.
23. Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, Van Leeuwen DG, Drakes DJ et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018 Oct;36(9):847-56. doi: 10.1038/nbt.4195, PMID 30102295.
24. Bupha-Intr O, Haeusler G, Chee L, Thursky K, Slavin M, Teh B. CAR-T cell therapy and infection: a review. Expert Rev Anti-Infect Ther. 2021 Jun 3;19(6):749-58. doi: 10.1080/14787210.2021.1855143, PMID 33249873.
25. Zheng PP, Kros JM, Li J. Approved CAR T cell therapies: ice bucket challenges on glaring safety risks and long-term impacts. Drug Discov Today. 2018 Jun 1;23(6):1175-82. doi: 10.1016/j.drudis.2018.02.012, PMID 29501911.
26. Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T cell therapy: A new era for cancer treatment (Review). Oncol Rep. 2019 Dec 1;42(6):2183-95. doi: 10.3892/or.2019.7335, PMID 31578576.
27. Bartoló-Ibars A, Uribe-Herranz M, Muñoz-Sánchez G, Arnaldos-Pérez C, Ortiz-Maldonado V, Urbano-Ispizua Á et al. CAR-T after stem cell transplantation in B-cell lymphoproliferative disorders: are they really autologous or allogenic cell therapies? Cancers. 2021 Sep 17;13(18):4664. doi: 10.3390/cancers13184664, PMID 34572890.
28. Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021 Dec;12(1):1.
29. Zhang XW, Wu YS, Xu TM, Cui MH. CAR-T cells in the treatment of ovarian cancer: A promising cell therapy. Biomolecules. 2023 Mar 2;13(3):465. doi: 10.3390/biom13030465, PMID 36979400.
30. Cheever A, Townsend M, O'Neill K. Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors. Cells. 2022 Nov 16;11(22):3626.
31. Razavi AS, Loskog A, Razi S, Rezaei N. The signaling and the metabolic differences of various CAR T cell designs. Int Immunopharmacol. 2023 Jan 1;114:109593. doi: 10.1016/j.intimp.2022.109593, PMID 36700773.
32. Vasic D, Lee JB, Leung Y, Khatri I, Na Y, Abate-Daga D et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022 Apr 22;7(70):eabl3642. doi: 10.1126/sciimmunol.abl3642, PMID 35452255.
33. Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022 Nov 24;22(1):365. doi: 10.1186/s12935-022-02778-6, PMID 36419058.
34. Foeng J, Comerford I, McColl SR. Harnessing the chemokine system to home CAR-T cells into solid tumors. Cell Rep Med. 2022 Mar 15;3(3):100543. doi: 10.1016/j.xcrm.2022.100543, PMID 35492880.
35. White LG, Goy HE, Rose AJ, McLellan AD. Controlling cell trafficking: addressing failures in CAR T and NK cell therapy of solid tumours. Cancers. 2022 Feb 15;14(4):978. doi: 10.3390/cancers14040978, PMID 35205725.
36. Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 2022 Nov 24;22(1):365. doi: 10.1186/s12935-022-02778-6, PMID 36419058.
37. Taromi S, Firat E, Simonis A, Braun LM, Apostolova P, Elze M et al. Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. Cancer Lett. 2022 Jul 10;538:215697. doi: 10.1016/j.canlet.2022.215697, PMID 35487310.
38. Liu X, Onda M, Watson N, Hassan R, Ho M, Bera TK et al. Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proc Natl Acad Sci USA. 2022 May 10;119(19):e2202439119. doi: 10.1073/pnas.2202439119.
39. Li H, Zhou X, Wang G, Hua D, Li S, Xu T et al. CAR-T cells targeting TSHR demonstrate safety and potent preclinical activity against differentiated thyroid cancer. J Clin Endocrinol Metab. 2022 Apr 1;107(4):1110-26. doi: 10.1210/clinem/dgab819, PMID 34751400.
40. Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S et al. Multifunctional mRNA-based CAR T cells display promising antitumor activity against glioblastoma. Clin Cancer Res. 2022 Nov 1;28(21):4747-56. doi: 10.1158/1078-0432.CCR-21-4384, PMID 36037304.
41. Sengsayadeth S, Savani BN, Oluwole O, Dholaria B. Overview of approved CAR- T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem. 2022 Jan;3;Suppl 1:6-10. doi: 10.1002/jha2.338, PMID 35844299.
42. Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022 Jun 10;13:927153. doi: 10.3389/fimmu.2022.927153, PMID 35757715.
43. Chen S, Zhang Y, Fang C, Zhang N, Wang Y, Chen R et al. Donor-derived and off-the-shelf allogeneic anti-CD19 CAR T-cell therapy for R/R ALL and NHL: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022 Sep 7;179:103807. doi: 10.1016/j.critrevonc.2022.103807, PMID 36087853.
44. Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. The J Am Soc Hematol. 2023 May 18;141(20):2430-42.
45. Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M et al. Rapid manufacturing of nonactivated potent CAR T.
46. Si X, Gu T, Liu L, Huang Y, Han Y, Qian P et al. Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective. Cancer Lett. 2022 Sep 17;550:215920. doi: 10.1016/j.canlet.2022.215920, PMID 36122628.
47. Xu N, Yang XF, Xue SL, Tan JW, Li MH, Ye J et al. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells. Biochem Biophys Res Commun. 2022 Mar 5;595:54-61. doi: 10.1016/j.bbrc.2022.01.070, PMID 35101664.
48. Beyar-Katz O, Perry C, On YB, Amit O, Gutwein O, Wolach O et al. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19

CAR-T cells—single-center experience. Ann Hematol. 2022 Aug;101(8):1769-76. doi: 10.1007/s00277-022-04889-6, PMID 35731278.

49. Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023 Jan 10;7(1):32-9. doi: 10.1182/bloodadvances.2022008525, PMID 36260735.
50. Tang JP, Peters CW, Quiros C, Wang X, Klomhaus AM, Yamada RE et al. Hypophosphatemia due to increased effector cell metabolic activity is associated with neurotoxicity symptoms in CD19-targeted CAR T-cell therapy. Cancer Immunol Res. 2022 Dec 2;10(12):1433-40. doi: 10.1158/2326-6066.CIR-22-0418, PMID 36259217.
51. Pan K, Farrukh H, Chittepu VC, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022 Dec;41(1):1-2.
52. Zhang Q, Zu C, Jing R, Feng Y, Zhang Y, Zhang M et al. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma. Front Immunol. 2023 May 4;14:1125357. doi: 10.3389/fimmu.2023.1125357, PMID 37215107.
53. Patel A, Levenson J, Huang J, Agha M, Dorritie K. Prevalence of orthostatic hypotension or frank hypotension after car-T hospitalization. J Am Coll Cardiol. 2021 May 11;77(18):3289-. doi: 10.1016/S0735-1097(21)04643-X.
54. Smith AJ, Oertle J, Warren D, Prato D. Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective. J Cell Immunother. 2016 Nov 1;2(2):59-68. doi: 10.1016/j.jocit.2016.08.001.
55. Geltink RIK, Kyle RL, Pearce EL. Unraveling the complex interplay between T cell metabolism and function. Annu Rev Immunol. 2018 Apr 26;36:461-88. doi: 10.1146/annurev-immunol-042617-053019, PMID 29677474.
56. Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, Van Leeuwen DG, Drakes DJ et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018 Oct;36(9):847-56. doi: 10.1038/nbt.4195, PMID 30102295.
57. Mao R, Kong W, He Y. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better. Front Immunol. 2022 Oct 17;13:1032403. doi: 10.3389/fimmu.2022.1032403, PMID 36325345.
58. Sadelain MCd. CD19 Car T cells. Cell. 2017 Dec 14;171(7):1471. doi: 10.1016/j.cell.2017.12.002, PMID 29245005.
59. Dabiri H, Safarzadeh Kozani P, Habibi Anbouhi M, Mirzaee Godarzee M, Haddadi MH, Basiri M et al. Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies. Biomark Res. 2023 Jul 4;11(1):67. doi: 10.1186/s40364-023-00509-1, PMID 37403182.